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Abstract
Rationale: Nitric oxide is an important regulator of vascular tone in the pulmonary circulation.
Surgical correction of congenital heart disease limits pulmonary hypertension to a brief period.
Objectives: The study has measured expression of endothelial (eNOS), inducible (iNOS), and
neuronal nitric oxide synthase (nNOS) in the lungs from biopsies of infants with pulmonary
hypertension secondary to cardiac abnormalities (n = 26), compared to a control group who did
not have pulmonary or cardiac disease (n = 8).
Methods: eNOS, iNOS and nNOS were identified by immunohistochemistry and quantified in
specific cell types.
Measurements and main results: Significant increases of eNOS and iNOS staining were found
in pulmonary vascular endothelial cells of patients with congenital heart disease compared to
control infants. These changes were confined to endothelial cells and not present in other cell
types. Patients who strongly expressed eNOS also had strong expression of iNOS.
Conclusion: Upregulation of eNOS and iNOS occurs at an early stage of pulmonary hypertension,
and may be a compensatory mechanism limiting the rise in pulmonary artery pressure.
Introduction
Nitric oxide (NO) plays a central role in the maintenance
of normal pulmonary vascular tone and healthy lung
function [1]. All 3 isoforms of nitric oxide synthase (NOS)
are present in the lungs and contribute to NO production
in specific cell types [2]. Pediatric pulmonary disease is
associated with endothelial dysfunction and conse-
quently reduced NO delivery from the pulmonary vascu-
lar endothelium [3]. Moreover there is evidence from
experimental models of neonatal pulmonary hyperten-
sion that impairment of NOS can generate reactive oxygen
species, leading to a further cycle of deterioration of the
vascular endothelium [4]. In adults with pulmonary arte-
rial hypertension it has been demonstrated that output of
NO is diminished [5], and that those patients who
responded well to therapy had corresponding improve-
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ment in exhaled NO [6]. NO status can be improved by
administration of inhaled NO which is valuable in the
management of infants with pulmonary hypertension [7-
10].
We chose to immunohistochemically investigate changes
in NOS expression during the early course of pulmonary
hypertension. Studies with experimental models of pul-
monary hypertension have shown upregulation of
endothelial NOS (eNOS) in the endothelial layer of both
large and small pulmonary arteries [11]. Increased expres-
sion of eNOS was due to the initiating stimulus (hypoxia)
and was not secondary to hyperperfusion [12]. The upreg-
ulation of eNOS correlated in time with the development
of pulmonary hypertension [13]. In cultured pulmonary
endothelial cells, acute exposure to hypoxia also upregu-
lated eNOS [14]. There are several molecular mechanisms
through which hypoxia can stimulate eNOS accumula-
tion in endothelial cells, including hypoxia inducible fac-
tor [15] and phosphorylated cyclic-AMP response element
binding protein (pCREB) [16]. Others have shown
decreased expression of eNOS during chronic hypoxia in
rats [17] and in human endothelial cells [18]. However in
patients with pulmonary hypertension, it is less clear what
changes in NOS isoform levels occur. In infants with con-
genital diaphragmatic hernia, it has been reported that
pulmonary endothelium levels of iNOS were decreased
[19] or unchanged [20], and similarly that pulmonary
vascular endothelium levels of eNOS were decreased [21]
or unaltered [19,20]. In adults with primary or secondary
pulmonary hypertension, eNOS was reduced in the
endothelial layer of small pulmonary arteries [22,23] but
increased in plexiform lesions [22]. Given that the clinical
studies have used patients with advanced disease whereas
the experimental animal studies looked at an early stage
of relatively mild pulmonary hypertension, we hypothe-
sised that eNOS is raised initially when pulmonary hyper-
tension is developing but falls at a late stage when
endothelium dysfunction becomes severe. The aims of the
present study were therefore to immunohistochemically
determine the expression of the three isoforms of NOS in
the lungs of infants with secondary pulmonary hyperten-
sion since they will have been exposed to elevated pulmo-
nary pressure for a relatively short time and may therefore
reveal what happens during the development of pulmo-
nary hypertension.
Methods
Patients
Patients (n = 26) had a mean age of 16.9 months (± SEM
= 4.02, median = 11 months, range: 2 months to 7 years)
and had cardiac surgery performed between December
1985 and October 1991 at the German Heart Institute,
Berlin, Germany. All patients had congenital cardiac
defects typically associated with pulmonary hypertension
and had a lung biopsy taken during corrective cardiac sur-
gery. Surgery markedly reduced systolic pulmonary artery
pressure with further reduction at follow up in patients,
from whom data were available (for patient details see
Table 1). Informed consent was obtained from the
infants' parents, and the study protocol had previously
been approved by the local institutional ethics committee.
Control subjects
Control infants (n = 8) were chosen from infants and chil-
dren having died from various non-pulmonary causes,
who had an autopsy performed at the Department of
Paidopathology, Humboldt University Berlin, Germany.
None of these patients had clinical or echocardiographic
evidence of pulmonary hypertension nor was there any
clinical or radiologic evidence of pulmonary infection.
Controls had a mean age of 7.1 months (± SEM = 1.75,
median: 6 months, range: 2 to 17 months). For control
details see Table 2.
Methodology for immunohistochemistry
Lung tissue was supplied as paraffin-embeded tissue
blocks. Sections (4 μm) were cut from the blocks, rehy-
drated and then treated for antigen retrieval by microwave
pressure cooking or trypsin incubation. The sections were
then treated to block non-specific binding of primary and
secondary antibodies and non-specific reaction with chro-
mogens as described previously [11]. Sections were then
incubated with the specific antibody for 60 minutes at
room temperature (eNOS: catalogue reference 610296,
BD Biosciences, UK, used at 1:1000 dilution along with
pressure cooking antigen retrieval; iNOS: catalogue refer-
ence 610328, BD Biosciences, UK, used at 1:500 dilution
along with pressure cooking antigen retrieval; nNOS: cat-
alogue reference 610308, BD Biosciences, UK, used at
1:400 dilution along with trypsin antigen retrieval).
Bound antibody was detected using goat anti-mouse IgG
conjugated with horseradish peroxidase using a streptavi-
din-biotin link, and visualized with diaminobenzidine. In
negative controls the primary antibody was replaced with
pre-immune serum. Sections were counterstained using
hematoxylin and viewed by light microscopy.
Staining intensity was quantified as follows: 0 = negative;
0.5 = faint/blush; 1 = mild; 2 = moderate. Separate quan-
tification was performed for eNOS in small artery
endothelium, small artery media, respiratory epithelium,
alveolar macrophages. Antibody dilutions were chosen in
order to differentiate between groups i.e. although there is
usually baseline expression of eNOS in controls; dilutions
were titrated until there was no eNOS expression visible in
controls. For iNOS and nNOS, quantification was carried
out in the same cell types except that alveolar macro-
phages and alveolar lining cells were combined. Vessels ofR
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Table 1: Patient details
dob sex Systolic 
PA-pressure 
pre-surgery
PVR dyn Systolic 
PA-pressure 
post-surgery
Systolic 
PA-pressure 
after 6-36 
months
Qp:Qs Rp:Rs Diagnosis Age at surgery 
(months)
Heath + 
Edwards
Rabinovich
26.12.1990 f 75 1178 24 17 7,2 0,01 complete atrio-
ventricular septal 
defect ventricular 
septal defect, atrial 
septal
52 a
28.03.1991 f 424 5 0,08 defect 6 2 b
20.01.1985 m 388 3 0,10 ventricular septal 
defect ventricular 
septal defect, atrial 
septal
11 2 b
20.03.1984 m 160 1,6 0,11 defect 60 1 a
20.10.1987 f 968 3,9 0,15 ventricular septal 
defect
12 2 c
03.12.1982 m 83 294 60 11 2,9 0,24 complete atrio-
ventricular septal 
defect
84 1 c
12.08.1988 f 100 2400 30 22 2,6 0,27 complete atrio-
ventricular septal 
defect ventricular 
septal defect, patent 
ductus
72 c
27.02.1991 f 1425 3,4 0,29 arteriosus, 
coarctation 
ventricular septal 
defect, atrial septal
61 a
25.11.1988 f 1855 2,8 0,30 defect 5 1 b
17.01.1985 f 80 2059 25 30 1,5 0,32 complete atrio-
ventricular septal 
defect
14 0 0
14.06.1988 f 75 2222 25 14 2,1 0,32 complete atrio-
ventricular septal 
defect single vessel 
disease, partial 
anomalous
51 b
09.03.1984 f 1285 1,9 0,33 pulmonary venous 
drainage
48 2 c
25.05.1990 m 2536 0,71 0,40 thoracic aortic 
constriction double-
outlet right ventricle, 
ventricular
21 bR
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17.10.1980 m 717 1,9 0,40 septal defect, 
coarctation
11 3 c
06.04.1987 m 982 2,1 0,40 complete atrio-
ventricular septal 
defect
19 1 c
15.05.1990 m 1883 35 2,3 0,41 ventricular septal 
defect
72 b
13.05.1988 f 1509 1,8 0,43 ventricular septal 
defect
11 2 0
10.02.1988 f 90 2061 38 18 1,8 0,45 complete atrio-
ventricular septal 
defect
12 2 0
18.05.1990 f 3593 0,83 0,47 complete atrio-
ventricular septal 
defect
41 a
22.09.1988 m 3537 1,2 0,50 atrial septal defect, 
patent ductus 
arteriosus
21 b
31.10.1989 m 2166 1,5 0,52 ventricular septal 
defect
11 1 b
03.11.1989 m 2617 1,4 0,71 mitral incompetence 11 2 a
05.04.1987 m 100 2135 25 35 1,6 0,71 ventricular septal 
defect
30 0 ?
06.10.1984 f 93 983 75 34 1 0,83 ventricular septal 
defect
48 4 c
24.10.1988 f 83 2143 35 14 1,5 0,83 complete atrio-
ventricular septal 
defect
62 b
25.05.1988 f 110 1888 40 1,3 0,90 ventricular septal 
defect
34 ?
(CAVSD: complete atrio-ventricular septal defect; ASD: atrial septal defect; VSD: ventricular septal defect; MI: mitral incompetence); n = 26
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an internal diameter of less than 250 μm were regarded as
small pulmonary arteries.
Statistics
For each antibody and cell type, the staining intensity of
the cardiac patients was compared to the staining inten-
sity of the normotensive patients using the Mann-Whit-
ney-U test. Spearman's correlation coefficient has been
calculated to describe the correlation between eNOS and
iNOS expression. Statistical significance was assumed at p
< 0.05.
Results
In all of the lung sections from infants with pulmonary
hypertension, thickening of the small pulmonary arteries
was evident. In contrast there were no abnormalities of
the pulmonary arteries in any normotensive control
patients. There was expression of eNOS in the endothelial
layer of small pulmonary arteries, the respiratory epithe-
lium, and alveolar macrophages. Expression of eNOS was
greatly increased in pulmonary hypertensive lungs com-
pared to control lungs in the pulmonary artery endothe-
lium (Figure 1, Figure 2). However there were no
significant differences between controls and patient
groups in staining for eNOS in alveolar macrophages and
in the respiratory epithelium. Expression of iNOS was
found in the small pulmonary arteries, both media and
endothelium, the respiratory epithelium, and in alveolar
macrophages/alveolar lining cells. There was significant
upregulation of iNOS in endothelial cells of pulmonary
hypertensive patients compared to control patients, but
there were no differences between the cases and controls
at any of the other cell types where iNOS was found (Fig-
ure 1, Figure 2). Expression of nNOS was very light in all
cell types in the lung and was not different between cases
and controls (Figure 1, Figure 2).
There was a significant correlation of eNOS and iNOS
staining intensity in the pulmonary artery endothelium,
such that patients having stronger staining in eNOS also
had higher levels of iNOS (Spearman's correlation coeffi-
cient 0.72, p = 0.0004).
Discussion
Here we report the consistent finding of an increase in
eNOS expression during conditions of increased pulmo-
nary vascular resistance secondary to congenital heart dis-
ease in infants and children. This upregulation appears to
be linked to pulmonary hypertension in that it occurs in
the pulmonary artery endothelium, but not in other sites
where eNOS is present and nor is there any change in
nNOS. We have previously shown increased expression of
eNOS in pulmonary endothelial cells in infants with per-
sistent pulmonary hypertension of the newborn (PPHN)
[24] and in congenital pulmonary lymphangiectasis [25].
Previous studies of NOS enzyme expression in patients
with pulmonary hypertension have examined either
adults with severe pulmonary hypertension of many
years' duration, or infants with congenital diaphragmatic
hernia who have very severe hypertension. Patients with
pulmonary hypertension classified as irreversible have
been shown to have higher levels of eNOS expression,
particularly in areas of severe vascular lesions [26]. Others
found isolated increases in iNOS immunoreactivity but
no changes in eNOS immunoreactivity in patients with
congenital heart disease and flow-associated pulmonary
hypertension [27]. The present study shows upregulation
Table 2: Controls
dob sex Age at death (months) Diagnosis PH
21.10.1992 f 5 Pulmonary stenosis no
21.12.1991 m 17 D-transposition of the great arteries no
04.08.1993 m 2 Hypoplastic left heart syndorme no
06.04.1993 f 9 Mitochondriopathy no
28.06.1993 m 10 Sudden infant death syndrome no
20.07.1995 m 7 Carnitine-Palmitoyl-Transferase-Defect Type I no
07.04.1996 f 2 Sudden infant death syndrome no
22.04.1996 f 5 Omenn syndrome no
(d-TGA: d-transposition of the great arteries; HLHS: hypoplastic left heart syndrome; SIDS: sudden infant death syndrome; CPT-defect: Carnitine-
Palmitoyl-Transferase-Defect); n = 8Respiratory Research 2009, 10:110 http://respiratory-research.com/content/10/1/110
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Lungs from infants with pulmonary hypertension (A, C, E) and from control patients of similar age (B, D, F) stained for (A and  B) eNOS, (C and D) iNOS, (E and F) nNOS Figure 1
Lungs from infants with pulmonary hypertension (A, C, E) and from control patients of similar age (B, D, F) 
stained for (A and B) eNOS, (C and D) iNOS, (E and F) nNOS. (A) Cardiac patient small pulmonary artery showing 
mild endothelial positivity for eNOS. Intra-alveolar macrophages and alveolar lining cells also positive with very mild positivity 
also noted in media. (B) Small pulmonary artery from control patient showing very mild endothelial positivity for eNOS. (C) 
Cardiac patient small pulmonary artery showing iNOS positivity in endothelium and media. Intra-alveolar macrophages stained 
also strongly positive. (D) Small pulmonary artery of control patient showing no significant iNOS positivity. Intra-alveolar mac-
rophages were positive. (E) Cardiac patient small pulmonary artery showing no immunocytochemical positivity for nNOS. (F) 
Control patient small pulmonary artery showing no positivity by immunocytochemistry for nNOS. × 400.Respiratory Research 2009, 10:110 http://respiratory-research.com/content/10/1/110
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Intensity of staining for (A) eNOS, (B) iNOS and (C) nNOS in lungs from infants with pulmonary hypertension and from con- trol patients of similar age Figure 2
Intensity of staining for (A) eNOS, (B) iNOS and (C) nNOS in lungs from infants with pulmonary hypertension 
and from control patients of similar age. (A) Staining for eNOS was quantified separately in pulmonary vascular endothe-
lium, respiratory endothelium, and alveolar macrophages of controls and cardiac patients (*p = 0.0001 comparing cases to con-
trols). (B) Staining for iNOS was quantified in pulmonary vascular endothelium, pulmonary vascular media, respiratory 
endothelium, and alveolar macrophages/alveolar lining cells of controls and cardiac patients (* p = 0.008 comparing cases to 
controls). (C) Staining intensity for iNOS was quantified in pulmonary vascular endothelium, respiratory endothelium, and alve-
olar macrophages/alveolar lining cells of controls and cardiac patients. n = 23 cases, n = 8 controls.Respiratory Research 2009, 10:110 http://respiratory-research.com/content/10/1/110
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of eNOS and iNOS at an early stage of pulmonary hyper-
tension, in agreement with the rat hypoxic model [11]
and in contrast to published studies of end stage disease
in pulmonary hypertensive patients [21-23]. This finding
is consistent with the hypothesis that increased eNOS is
associated with the initiation of pulmonary hypertension
(chronic hypoxic model in rats and infants with pulmo-
nary hypertension secondary to cardiac abnormalities)
whereas at a late stage there is severe damage to the
endothelium resulting in loss of eNOS. The decrease of
eNOS expression with longstanding disease in adulthood
[23] can be interpreted as the result of secondary damage
to the pulmonary vasculature caused by a prolonged
period of pulmonary hypertension, resulting in a failing
endothelium with reduced production of NO. Addition-
ally there may be other differences between infants and
adult patients other than the duration of pulmonary
hypertension which may have subtle effects on NOS
expression.
The importance of NOS is demonstrated by the finding
that mice with eNOS deletion have pulmonary hyperten-
sion [28]. However studies of animals that have either
deletion or over-expression of eNOS and iNOS reveal that
the physiological consequences of alterations in NOS
abundance are complex. As expected, agonist contractions
and HPV were both inhibited by gene delivery of either
iNOS or of eNOS [29,30], however surprisingly there was
no improvement in endothelium-dependent pulmonary
relaxation [29]. Deletion of eNOS gene was associated
with increased pulmonary artery muscularity, right ven-
tricular hypertrophy and right ventricular pressure, but
only in male and not in female mice [31]. Deletion of
iNOS was not associated with evidence of pulmonary
hypertension [31], however iNOS transfected mice had
increased expression lasting only 7 days [30] making these
experiments hard to interpret. Since eNOS deletion mice
had upregulation of iNOS [28] it is clear that expression
patterns of NOS isoforms are coupled. Thus the over-
expression of eNOS and iNOS that we found in infants
with pulmonary hypertension suggests but does not prove
that this is a compensatory mechanism limiting the rise in
pulmonary artery pressure. It is of interest that in our
study patients with the more extreme upregulation of
eNOS also had greater upregulation of iNOS, suggesting
that changes in both isoforms are linked in the process of
adaptation to pulmonary hypertension.
Our present data indicate that upregulation of eNOS is
not a short term effect as might be anticipated in cases of
PPHN. Rather can this increased expression of eNOS per-
sist over months and years as shown in our oldest patients
at the age of 5 and 7 years, respectively (Table 1).
Limitations of this study include the lack of enzyme activ-
ity data and the subjectivity of the immunohistochemical
findings. We have consequently minimized the effect of
confounding factors on the immunohistochemical data
by applying strict protocols of quantification of staining
intensity. The advantage of immunohistochemical studies
is the microtopographic localization of the protein under
investigation, which we regard as very important for the
specific question of our study. Although protein activity
studies would further strengthen the results of our investi-
gation, unfortunately we had only paraffin blocks of lung
tissue available thus preventing further protein activity
studies.
In summary, we have shown upregulation of eNOS and
iNOS in pulmonary endothelial cells at an early stage of
pulmonary hypertension in infants with congenital heart
disease. Additionally there is co-expression of these two
enzymes in pulmonary endothelial cells of these infants.
These findings support the hypothesis that infant pulmo-
nary hypertension is different from adult disease and
potentially more amenable to the therapeutic effect of
anti-proliferative medication and thus prevention of early
endstage pulmonary vascular disease.
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